[go: up one dir, main page]

PE20061075A1 - Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior - Google Patents

Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior

Info

Publication number
PE20061075A1
PE20061075A1 PE2005001499A PE2005001499A PE20061075A1 PE 20061075 A1 PE20061075 A1 PE 20061075A1 PE 2005001499 A PE2005001499 A PE 2005001499A PE 2005001499 A PE2005001499 A PE 2005001499A PE 20061075 A1 PE20061075 A1 PE 20061075A1
Authority
PE
Peru
Prior art keywords
patients
autoimmune diseases
combination
vegf antibodies
previous therapy
Prior art date
Application number
PE2005001499A
Other languages
English (en)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20061075A1 publication Critical patent/PE20061075A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN ANTICUERPO ANTAGONISTA DE LA ANGIOGENESIS, EL CUAL ES UN ANTICUERPO ANTI-VEGF TAL COMO BEVACIZUMAB. DICHO ANTAGONISTA DE ANGIOGENESIS PUEDE ADMINISTRARSE EN COMBINACION CON O EN SERIE DE UN AGENTE DMARD TAL COMO EL MTX O EN COMBINACION CON O EN SERIE CON UN INHIBIDOR DE TNF ALFA TAL COMO ETANERCEPT, INFLIXIMAB O ADALIMUMAB O EN COMBINACION O EN SERIE DE UN ANTAGONISTA QUE SE ENLAZA CON UN MARCADOR SUPERFICIAL DE LA CELULA B TAL COMO CD10, CD20, CD19, ENTRE OTROS. PARTICULARMENTE, EL ANTAGONISTA DE ANGIOGENESIS QUE COMPRENDE UN ANTICUERPO CONTRA CD20 PUEDE SER RITUXIMAB O 2H7 V16 HUMANIZADO. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES EN PACIENTES EN QUIENES HA FALLADO UN TRATAMIENTO ANTERIOR CON DMARDS O INHIBIDORES TNF ALFA
PE2005001499A 2004-12-17 2005-12-16 Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior PE20061075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
PE20061075A1 true PE20061075A1 (es) 2006-11-15

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001499A PE20061075A1 (es) 2004-12-17 2005-12-16 Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior

Country Status (23)

Country Link
US (2) US20060134111A1 (es)
EP (1) EP1824885A1 (es)
JP (1) JP2008524241A (es)
KR (1) KR20070086218A (es)
CN (1) CN101120020A (es)
AR (1) AR052056A1 (es)
AU (1) AU2005316403A1 (es)
BR (1) BRPI0518105A (es)
CA (1) CA2587932A1 (es)
CR (1) CR9181A (es)
IL (1) IL183347A0 (es)
MA (1) MA29366B1 (es)
MX (1) MX2007007165A (es)
NO (1) NO20073651L (es)
NZ (1) NZ555286A (es)
PE (1) PE20061075A1 (es)
RU (1) RU2007126970A (es)
SG (1) SG158089A1 (es)
SV (1) SV2006002342A (es)
TN (1) TNSN07191A1 (es)
TW (1) TW200634026A (es)
WO (1) WO2006066086A1 (es)
ZA (1) ZA200704898B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254174T3 (es) * 1999-05-07 2006-06-16 Genentech, Inc. Tratamiento de enfermedades autoinmunes con antagonistas que se unen a marcadores de superficie de linfocitos b.
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
KR101364902B1 (ko) * 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
PL1804835T3 (pl) 2004-09-13 2010-11-30 Genzyme Corp Konstrukty multimeryczne
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
EP2727996A1 (en) * 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
SMT202500126T1 (it) * 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
ES2440565T3 (es) * 2008-12-23 2014-01-29 Merck Patent Gmbh Biomarcadores para inhibidores con actividad anti-angiogénica
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
ES2652508T3 (es) 2010-08-06 2018-02-02 Genzyme Corporation Composiciones de antagonistas de VEGF y sus usos
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2015153514A1 (en) * 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
ES2622983T3 (es) * 2015-02-11 2017-07-10 Deutsches Krebsforschungszentrum Terapia contra el cáncer con un parvovirus combinado con bevacizumab
JP7319992B2 (ja) 2018-03-09 2023-08-02 アジェナス インコーポレイテッド 抗ｃｄ７３抗体およびそれらの使用方法
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6887468B1 (en) * 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
EP1824885A1 (en) 2007-08-29
RU2007126970A (ru) 2009-01-27
JP2008524241A (ja) 2008-07-10
US20060134111A1 (en) 2006-06-22
NZ555286A (en) 2010-04-30
CR9181A (es) 2008-07-31
AU2005316403A1 (en) 2006-06-22
WO2006066086A1 (en) 2006-06-22
KR20070086218A (ko) 2007-08-27
ZA200704898B (en) 2009-03-25
IL183347A0 (en) 2007-09-20
NO20073651L (no) 2007-09-10
AR052056A1 (es) 2007-02-28
TNSN07191A1 (en) 2008-11-21
SV2006002342A (es) 2006-06-01
SG158089A1 (en) 2010-01-29
TW200634026A (en) 2006-10-01
CN101120020A (zh) 2008-02-06
US20080214789A1 (en) 2008-09-04
MA29366B1 (fr) 2008-04-01
MX2007007165A (es) 2007-08-14
BRPI0518105A (pt) 2008-11-04
CA2587932A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PE20061075A1 (es) Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior
KR102809079B1 (ko) 항-cd19 항체 및 브루톤 타이로신 키나제 억제제의 조합 및 이의 용도
JP6114273B2 (ja) 抗−ｃｄ１９抗体とプリン類似体の併用治療
CY1111703T1 (el) Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
AU2022202800B2 (en) Combinations and uses thereof
PE20201146A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
JP2017507953A5 (es)
PE20050928A1 (es) Combinaciones terapeuticas de anticuerpo anti-igfr1
KR102115203B1 (ko) 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
PE20160999A1 (es) Metodos para administrar anticuerpos anti-tnf-alfa
MX2010005099A (es) Usos de anticuerpos anti-cd40.
AU2017348624B2 (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
JP2014525925A5 (es)
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
JP2014525926A5 (es)
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2023001836A1 (es) Tratamiento de glomerulopatía c3 usando un inhibidor de c5a
AR077848A1 (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
AR110470A1 (es) Terapia de combinación para tratar la enfermedad de alzheimer
RU2008140661A (ru) Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
Zent Monoclonal antibody therapy in chronic lymphocytic leukemia
AR115106A1 (es) Método de tratamiento de cánceres y de potenciación de la eficacia de terapéuticas de redireccionamiento de células t
Delfino et al. Brentuximab vedotin in CD30-expressing cutaneous T-cell lymphoma
NZ749159A (en) Anti-canine platelet derived growth factor receptor alpha antibody

Legal Events

Date Code Title Description
FC Refusal